{"id": "article-27562_0", "title": "Posttransplantation Cancer -- Continuing Education Activity", "content": "Cancer is one of the three major causes of death after an organ transplant. Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Knowledge of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. In this activity, we focus on the epidemiology, pathophysiology, presentation, diagnosis, screening and highlight the role of the interprofessional team in its treatment strategy.", "contents": "Posttransplantation Cancer -- Continuing Education Activity. Cancer is one of the three major causes of death after an organ transplant. Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Knowledge of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. In this activity, we focus on the epidemiology, pathophysiology, presentation, diagnosis, screening and highlight the role of the interprofessional team in its treatment strategy."}
{"id": "article-27562_1", "title": "Posttransplantation Cancer -- Continuing Education Activity", "content": "Objectives: Identify the etiology of post-transplant cancer. Review the pathophysiology of post-transplant cancer. Outline the treatment and management options available for post-transplant cancer. Discuss interprofessional team strategies for improving care coordination and communication to advance the treatment of post-transplant cancer and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Posttransplantation Cancer -- Continuing Education Activity. Objectives: Identify the etiology of post-transplant cancer. Review the pathophysiology of post-transplant cancer. Outline the treatment and management options available for post-transplant cancer. Discuss interprofessional team strategies for improving care coordination and communication to advance the treatment of post-transplant cancer and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-27562_2", "title": "Posttransplantation Cancer -- Introduction", "content": "Organ transplant is the only way to extend the lives of many patients with end-stage organ failure. This procedure is not without the associated risks involved since the time of its inception. Cancer is one of the three major causes of death after an organ transplant. [1] Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Understanding of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. The risk factor\u00a0is most elusive because of altered dynamics of immunity, host response, and different clinical presentation.\u00a0 Studies have shown an overall two to four-fold elevated risk of cancer after the organ transplant. [2] The mechanisms involved in the oncogenesis are long-term immunosuppression leading to reduced immune surveillance of neoplastic cells, and the opportunistic post-transplant infections especially viral infections because of Epstein-Barr virus (EBV), Varicella, Cytomegalovirus (CMV), and Human herpesvirus (HHV)-8, etc. [3] Physicians and patients face a challenging problem that cancer after an organ transplant is more biologically aggressive and patients may receive less aggressive cancer treatment because of comorbidities and the fear of transplant rejection. In this article, we will discuss the epidemiology, pathophysiology, presentation, diagnosis, screening and treatment strategy for cancer after organ transplantation.", "contents": "Posttransplantation Cancer -- Introduction. Organ transplant is the only way to extend the lives of many patients with end-stage organ failure. This procedure is not without the associated risks involved since the time of its inception. Cancer is one of the three major causes of death after an organ transplant. [1] Cardiovascular disease and infection are the other two reasons for death after an organ transplant, but they both are decreasing in frequency because of effective screening, prophylaxis, and interventional therapies. Understanding of post-transplant malignancy is inadequate regarding early detection and lack of established guidelines. The risk factor\u00a0is most elusive because of altered dynamics of immunity, host response, and different clinical presentation.\u00a0 Studies have shown an overall two to four-fold elevated risk of cancer after the organ transplant. [2] The mechanisms involved in the oncogenesis are long-term immunosuppression leading to reduced immune surveillance of neoplastic cells, and the opportunistic post-transplant infections especially viral infections because of Epstein-Barr virus (EBV), Varicella, Cytomegalovirus (CMV), and Human herpesvirus (HHV)-8, etc. [3] Physicians and patients face a challenging problem that cancer after an organ transplant is more biologically aggressive and patients may receive less aggressive cancer treatment because of comorbidities and the fear of transplant rejection. In this article, we will discuss the epidemiology, pathophysiology, presentation, diagnosis, screening and treatment strategy for cancer after organ transplantation."}
{"id": "article-27562_3", "title": "Posttransplantation Cancer -- Etiology", "content": "The risk factors for post-transplant malignancy are the patient, transplant, and medication-related.", "contents": "Posttransplantation Cancer -- Etiology. The risk factors for post-transplant malignancy are the patient, transplant, and medication-related."}
{"id": "article-27562_4", "title": "Posttransplantation Cancer -- Etiology -- Patient-related Risk Factors", "content": "The advanced\u00a0age of the patient is a well-described risk factor, and it\u00a0is an established\u00a0risk factor for the development of skin cancer. Sun exposure, prior history of cancer in a transplant recipient are also strong risk factors. Acuna et al. in their meta-analysis showed that pre-transplant malignancy correlates with an increased risk of cancer-specific mortality and of developing de novo malignancies after transplantation, compared with solid organ transplant recipients without a pretransplant malignancy. [4] Smoking and alcohol consumption are risk\u00a0factors for carcinogenesis and carry a high risk of mortality. [5] Viruses implicated in carcinogenesis include Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8), human papillomavirus (HPV), the Merkel cell polyomavirus, hepatitis B, and hepatitis C. EBV is implicated in the development of Hodgkin disease, Non-Hodgkin lymphoma, and other manifestations of PTLD, nasopharyngeal cancers and leiomyosarcomas. [6]", "contents": "Posttransplantation Cancer -- Etiology -- Patient-related Risk Factors. The advanced\u00a0age of the patient is a well-described risk factor, and it\u00a0is an established\u00a0risk factor for the development of skin cancer. Sun exposure, prior history of cancer in a transplant recipient are also strong risk factors. Acuna et al. in their meta-analysis showed that pre-transplant malignancy correlates with an increased risk of cancer-specific mortality and of developing de novo malignancies after transplantation, compared with solid organ transplant recipients without a pretransplant malignancy. [4] Smoking and alcohol consumption are risk\u00a0factors for carcinogenesis and carry a high risk of mortality. [5] Viruses implicated in carcinogenesis include Epstein-Barr virus (EBV), human herpesvirus 8 (HHV-8), human papillomavirus (HPV), the Merkel cell polyomavirus, hepatitis B, and hepatitis C. EBV is implicated in the development of Hodgkin disease, Non-Hodgkin lymphoma, and other manifestations of PTLD, nasopharyngeal cancers and leiomyosarcomas. [6]"}
{"id": "article-27562_5", "title": "Posttransplantation Cancer -- Etiology -- Transplant-related Risk Factors", "content": "Differences in the type of\u00a0transplant (living versus deceased) correlate with cancer risk. Patients\u00a0who receive\u00a0kidneys from\u00a0a living\u00a0donor\u00a0have a lower risk for genitourinary cancer and PTLD. [7] Donor transmission as a cause of post-transplant malignancy is a rare but is a documented\u00a0way of carcinogenesis; melanoma, cancer of lung, breast, colon, rectum,\u00a0kidney, Kaposi sarcoma, and glioblastoma multiforme all have\u00a0been reported to be\u00a0transmittable from donors. [8]", "contents": "Posttransplantation Cancer -- Etiology -- Transplant-related Risk Factors. Differences in the type of\u00a0transplant (living versus deceased) correlate with cancer risk. Patients\u00a0who receive\u00a0kidneys from\u00a0a living\u00a0donor\u00a0have a lower risk for genitourinary cancer and PTLD. [7] Donor transmission as a cause of post-transplant malignancy is a rare but is a documented\u00a0way of carcinogenesis; melanoma, cancer of lung, breast, colon, rectum,\u00a0kidney, Kaposi sarcoma, and glioblastoma multiforme all have\u00a0been reported to be\u00a0transmittable from donors. [8]"}
{"id": "article-27562_6", "title": "Posttransplantation Cancer -- Etiology -- Medication-related Risk Factors", "content": "The immunosuppressive drugs impair\u00a0immunosurveillance of neoplastic cells and increase the incidence of virally induced malignancies. The type, intensity, and duration of immunosuppressive therapy all influence the rate of carcinogenesis. These immunosuppressive drugs, for example, biologic agents (anti-thymocyte globulin, basiliximab), corticosteroids, antimetabolites (azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), and mTOR\u00a0inhibitors (rapamycin [sirolimus], everolimus) all\u00a0have been implicated. [9]", "contents": "Posttransplantation Cancer -- Etiology -- Medication-related Risk Factors. The immunosuppressive drugs impair\u00a0immunosurveillance of neoplastic cells and increase the incidence of virally induced malignancies. The type, intensity, and duration of immunosuppressive therapy all influence the rate of carcinogenesis. These immunosuppressive drugs, for example, biologic agents (anti-thymocyte globulin, basiliximab), corticosteroids, antimetabolites (azathioprine, mycophenolate mofetil), calcineurin inhibitors (cyclosporine, tacrolimus), and mTOR\u00a0inhibitors (rapamycin [sirolimus], everolimus) all\u00a0have been implicated. [9]"}
{"id": "article-27562_7", "title": "Posttransplantation Cancer -- Epidemiology", "content": "The Israel Penn International Transplant Tumor Registry (IPITTR), [10] the largest and most comprehensive registry in the world records non-melanoma skin cancers (NMSCs) as the most prevalent cancer in post organ transplant state. Following is the list of various cancers associated with the organ transplant: Kaposi sarcoma Skin (nonmelanoma, nonepithelial) Non-Hodgkin lymphoma Liver Anus Vulva Lip Other common malignancies with a statistically significant (p<0.001) increase included Lung Kidney Colon and rectum Pancreas Hodgkin's lymphoma Melanoma", "contents": "Posttransplantation Cancer -- Epidemiology. The Israel Penn International Transplant Tumor Registry (IPITTR), [10] the largest and most comprehensive registry in the world records non-melanoma skin cancers (NMSCs) as the most prevalent cancer in post organ transplant state. Following is the list of various cancers associated with the organ transplant: Kaposi sarcoma Skin (nonmelanoma, nonepithelial) Non-Hodgkin lymphoma Liver Anus Vulva Lip Other common malignancies with a statistically significant (p<0.001) increase included Lung Kidney Colon and rectum Pancreas Hodgkin's lymphoma Melanoma"}
{"id": "article-27562_8", "title": "Posttransplantation Cancer -- Pathophysiology", "content": "Transplant-related malignancies arise from an interplay of immunologic and nonimmunologic risk factors. The following is a brief description of the various pathways for the oncogenesis:", "contents": "Posttransplantation Cancer -- Pathophysiology. Transplant-related malignancies arise from an interplay of immunologic and nonimmunologic risk factors. The following is a brief description of the various pathways for the oncogenesis:"}
{"id": "article-27562_9", "title": "Posttransplantation Cancer -- Pathophysiology", "content": "Immunosuppressive agents and oncogenesis: calcineurin inhibitors stimulate carcinogenesis by inhibiting DNA repair mechanisms, apoptosis, and enhancing the production of interleukin 2 (IL-2),\u00a0transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). Transforming growth factor promotes tumor growth by regulating tumor cell invasion, metastatic potential, and VEGF stimulates neo-angiogenesis. Azathioprine increases cancer risk by causing post-replicative DNA mismatch repair. Sirolimus, everolimus and mycophenolate mofetil are not associated with an increased risk of cancer; they actually\u00a0have antiproliferative properties.", "contents": "Posttransplantation Cancer -- Pathophysiology. Immunosuppressive agents and oncogenesis: calcineurin inhibitors stimulate carcinogenesis by inhibiting DNA repair mechanisms, apoptosis, and enhancing the production of interleukin 2 (IL-2),\u00a0transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). Transforming growth factor promotes tumor growth by regulating tumor cell invasion, metastatic potential, and VEGF stimulates neo-angiogenesis. Azathioprine increases cancer risk by causing post-replicative DNA mismatch repair. Sirolimus, everolimus and mycophenolate mofetil are not associated with an increased risk of cancer; they actually\u00a0have antiproliferative properties."}
{"id": "article-27562_10", "title": "Posttransplantation Cancer -- Pathophysiology", "content": "Viral Infection and oncogenesis:\u00a0Transplant patients are vulnerable to viral infection or reactivation of latent infection. EBV promotes the oncogenesis by\u00a0reduced lymphocyte regulation, a lack of control of the oncogenic virus by EBV-specific CD81 cytotoxic T-cells, and proliferation of EBV-infected B cells.\u00a0The mechanism by which HHV-8 induces oncogenesis has not been completely elucidated. HHV-8\u2019s proinflammatory proteins might directly inhibit apoptosis and promote cell transformation. [11]", "contents": "Posttransplantation Cancer -- Pathophysiology. Viral Infection and oncogenesis:\u00a0Transplant patients are vulnerable to viral infection or reactivation of latent infection. EBV promotes the oncogenesis by\u00a0reduced lymphocyte regulation, a lack of control of the oncogenic virus by EBV-specific CD81 cytotoxic T-cells, and proliferation of EBV-infected B cells.\u00a0The mechanism by which HHV-8 induces oncogenesis has not been completely elucidated. HHV-8\u2019s proinflammatory proteins might directly inhibit apoptosis and promote cell transformation. [11]"}
{"id": "article-27562_11", "title": "Posttransplantation Cancer -- History and Physical", "content": "Although early cancer diagnosis may show improvement of cancer outcomes in the cancer population, the reduced life expectancy and multiple comorbidities that exist in organ transplant recipients\u00a0regular\u00a0physical examination and history are of paramount importance.\u00a0On average, the age at diagnosis of post-transplant cancer is 40 years and the time from transplantation is the 3 to 5 years. [12] However, these numbers vary according to the cancer subtype, with lymphoma and Kaposi sarcoma occurring early after transplantation and epithelial cancers later on. The\u00a0specific questions on\u00a0history taking that\u00a0are of paramount importance are the\u00a0amount of high sun exposure, any skin health concerns, and the onset of irregular skin lesions, as\u00a0they all\u00a0point towards the onset of skin malignancy. Studies have shown that continued consumption of alcohol and smoking lead to early and aggressive squamous cell malignancy and urinary bladder cancer. If there is a concern for fever, weight loss or any neurological disturbance, then radiological investigations should be\u00a0performed\u00a0to rule out PTLD. If the patient endorses lower GI bleed, then threshold to examine colon to rule out malignancy should be low. The history taking in patients with solid organ transplant is more vigorous and frequent than the general population. Physical examination should\u00a0be carried out keeping in mind all the secondary cancers that may arise. Regular skin and\u00a0breast examination should be performed in the office, a digital rectal exam to detect early prostate cancer, and neurological examination to\u00a0clinically\u00a0rule out CNS lymphoma and PTLD. [13]", "contents": "Posttransplantation Cancer -- History and Physical. Although early cancer diagnosis may show improvement of cancer outcomes in the cancer population, the reduced life expectancy and multiple comorbidities that exist in organ transplant recipients\u00a0regular\u00a0physical examination and history are of paramount importance.\u00a0On average, the age at diagnosis of post-transplant cancer is 40 years and the time from transplantation is the 3 to 5 years. [12] However, these numbers vary according to the cancer subtype, with lymphoma and Kaposi sarcoma occurring early after transplantation and epithelial cancers later on. The\u00a0specific questions on\u00a0history taking that\u00a0are of paramount importance are the\u00a0amount of high sun exposure, any skin health concerns, and the onset of irregular skin lesions, as\u00a0they all\u00a0point towards the onset of skin malignancy. Studies have shown that continued consumption of alcohol and smoking lead to early and aggressive squamous cell malignancy and urinary bladder cancer. If there is a concern for fever, weight loss or any neurological disturbance, then radiological investigations should be\u00a0performed\u00a0to rule out PTLD. If the patient endorses lower GI bleed, then threshold to examine colon to rule out malignancy should be low. The history taking in patients with solid organ transplant is more vigorous and frequent than the general population. Physical examination should\u00a0be carried out keeping in mind all the secondary cancers that may arise. Regular skin and\u00a0breast examination should be performed in the office, a digital rectal exam to detect early prostate cancer, and neurological examination to\u00a0clinically\u00a0rule out CNS lymphoma and PTLD. [13]"}
{"id": "article-27562_12", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Screening and early detection of cancers is the best form of treatment. Below are the recommendations for the screening of the specific malignancy. [14]", "contents": "Posttransplantation Cancer -- Treatment / Management. Screening and early detection of cancers is the best form of treatment. Below are the recommendations for the screening of the specific malignancy. [14]"}
{"id": "article-27562_13", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Breast cancer: Women 50 to 69 years: annual screening mammography with or without clinical breast examination is the current recommendation. At age 40 to 49 years: the benefit of screening is less certain and the ultimate\u00a0decision\u00a0is up to the\u00a0clinician and patient. In females above 70 years of age: annual screening is appropriate as long as estimated life expectancy is about 8 years.", "contents": "Posttransplantation Cancer -- Treatment / Management. Breast cancer: Women 50 to 69 years: annual screening mammography with or without clinical breast examination is the current recommendation. At age 40 to 49 years: the benefit of screening is less certain and the ultimate\u00a0decision\u00a0is up to the\u00a0clinician and patient. In females above 70 years of age: annual screening is appropriate as long as estimated life expectancy is about 8 years."}
{"id": "article-27562_14", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Liver cancer: Patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound should be performed every 6 to 12 months.", "contents": "Posttransplantation Cancer -- Treatment / Management. Liver cancer: Patients with chronic hepatitis B or C and cirrhosis, serum AFP and liver ultrasound should be performed every 6 to 12 months."}
{"id": "article-27562_15", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "PTLD:\u00a0Complete history and physical examination should take place every three months, particularly in the first posttransplant year.", "contents": "Posttransplantation Cancer -- Treatment / Management. PTLD:\u00a0Complete history and physical examination should take place every three months, particularly in the first posttransplant year."}
{"id": "article-27562_16", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Anogenital: Early physical examination of the anogenital area, including a pelvic examination and cytologic studies for women. There is insufficient evidence to recommend either for or against screening anoscopy and biopsies of the anal epithelium.", "contents": "Posttransplantation Cancer -- Treatment / Management. Anogenital: Early physical examination of the anogenital area, including a pelvic examination and cytologic studies for women. There is insufficient evidence to recommend either for or against screening anoscopy and biopsies of the anal epithelium."}
{"id": "article-27562_17", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Cervical:\u00a0All women aged above 18 years and sexually active girls <18 years old should undergo an annual pelvic examination and Pap smear.", "contents": "Posttransplantation Cancer -- Treatment / Management. Cervical:\u00a0All women aged above 18 years and sexually active girls <18 years old should undergo an annual pelvic examination and Pap smear."}
{"id": "article-27562_18", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Skin cancers: Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening.", "contents": "Posttransplantation Cancer -- Treatment / Management. Skin cancers: Examination of skin, conjunctivae, and oropharyngeal mucosa annually; patients at higher risk (ethnicity, geographic area of residence or serologic positivity for HHV) may benefit from more frequent screening."}
{"id": "article-27562_19", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Careful screening of the patient and donor before transplantation to help detect an underlying pre-existing malignancy is one of the effective ways to avoid dealing with this enigmatic problem later on. We have tried to summarize\u00a0the broad topic of management and cancer in solid organ recipients into general recommendations;", "contents": "Posttransplantation Cancer -- Treatment / Management. Careful screening of the patient and donor before transplantation to help detect an underlying pre-existing malignancy is one of the effective ways to avoid dealing with this enigmatic problem later on. We have tried to summarize\u00a0the broad topic of management and cancer in solid organ recipients into general recommendations;"}
{"id": "article-27562_20", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Reduction of immunosuppression: Reduction or cessation of immunosuppressive therapy is useful primarily in patients who had a renal transplant since the\u00a0loss of the graft to rejection is not a fatal event in these patients. Such measures may cause tumor regression sometimes\u00a0such as\u00a0 PTLD,\u00a0some skin cancers, Kaposi sarcoma (KS). [15] The reduction in\u00a0calcineurin inhibitor exposure\u00a0may be important.", "contents": "Posttransplantation Cancer -- Treatment / Management. Reduction of immunosuppression: Reduction or cessation of immunosuppressive therapy is useful primarily in patients who had a renal transplant since the\u00a0loss of the graft to rejection is not a fatal event in these patients. Such measures may cause tumor regression sometimes\u00a0such as\u00a0 PTLD,\u00a0some skin cancers, Kaposi sarcoma (KS). [15] The reduction in\u00a0calcineurin inhibitor exposure\u00a0may be important."}
{"id": "article-27562_21", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Anogenital cancers: In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical fluorouracil.\u00a0Invasive tumors require wide local excision (e.g., APR), with inguinal lymphadenectomy. Visceral malignancy :\u00a0Visceral malignancies are to receive treatment by standard surgical, radiotherapeutic, or chemotherapeutic modalities.", "contents": "Posttransplantation Cancer -- Treatment / Management. Anogenital cancers: In situ anogenital cancers can be treated with laser therapy, electrocautery, or topical fluorouracil.\u00a0Invasive tumors require wide local excision (e.g., APR), with inguinal lymphadenectomy. Visceral malignancy :\u00a0Visceral malignancies are to receive treatment by standard surgical, radiotherapeutic, or chemotherapeutic modalities."}
{"id": "article-27562_22", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Post-transplant lymphoproliferative disorder (PTLD) :\u00a0Management of PTLD deserves special mention as the treatment has undergone major changes over time.\u00a0The main options for initial treatment are the reduction of immunosuppression, immunotherapy with the CD20 monoclonal antibody\u00a0(rituximab), chemotherapy, radiation therapy, or a combination of these. The PTLD classifies into four types and treatment varies according to the type.", "contents": "Posttransplantation Cancer -- Treatment / Management. Post-transplant lymphoproliferative disorder (PTLD) :\u00a0Management of PTLD deserves special mention as the treatment has undergone major changes over time.\u00a0The main options for initial treatment are the reduction of immunosuppression, immunotherapy with the CD20 monoclonal antibody\u00a0(rituximab), chemotherapy, radiation therapy, or a combination of these. The PTLD classifies into four types and treatment varies according to the type."}
{"id": "article-27562_23", "title": "Posttransplantation Cancer -- Treatment / Management", "content": "Early lesions:  Reduction of immunosuppression alone suffices. Polymorphic PTLD: They express CD20, so besides the reduction in immunosuppression rituximab is advised. Surgery is reserved for patients with minimal localized residual disease. Monomorphic PTLD: For CD20+ PTLD, reduction in immunosuppression with rituximab and combination of systemic chemotherapy\u00a0such as CHOP (cyclophosphamide, vincristine, prednisone) is the therapeutic recommendation. If the tumor is CD20 negative, then systemic chemotherapy is administered along with the reduction in immunosuppression.\u00a0Surgery is only for patients with complications such as perforation or obstruction of the hollow viscus such as the bowel. Classic Hodgkin lymphoma-like PTLD\u2013Classic Hodgkin lymphoma-like PTLD is the least common form. Data regarding its management is lacking. Treatment is according to the protocols used for classic Hodgkin lymphoma. [16] [17]", "contents": "Posttransplantation Cancer -- Treatment / Management. Early lesions:  Reduction of immunosuppression alone suffices. Polymorphic PTLD: They express CD20, so besides the reduction in immunosuppression rituximab is advised. Surgery is reserved for patients with minimal localized residual disease. Monomorphic PTLD: For CD20+ PTLD, reduction in immunosuppression with rituximab and combination of systemic chemotherapy\u00a0such as CHOP (cyclophosphamide, vincristine, prednisone) is the therapeutic recommendation. If the tumor is CD20 negative, then systemic chemotherapy is administered along with the reduction in immunosuppression.\u00a0Surgery is only for patients with complications such as perforation or obstruction of the hollow viscus such as the bowel. Classic Hodgkin lymphoma-like PTLD\u2013Classic Hodgkin lymphoma-like PTLD is the least common form. Data regarding its management is lacking. Treatment is according to the protocols used for classic Hodgkin lymphoma. [16] [17]"}
{"id": "article-27562_24", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "Differential diagnosis:", "contents": "Posttransplantation Cancer -- Differential Diagnosis. Differential diagnosis:"}
{"id": "article-27562_25", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "PTLD: Infectious complications streptococcal pharyngitis and Infectious mononucleosis\u00a0in an immunosuppressed\u00a0individual presenting with fever, pharyngitis, and cervical lymphadenopathy closely mimic PTLD. Solid-organ recipients with opportunistic pulmonary infections such as aspergillosis and acute graft-versus-host disease may develop multiple lung parenchymal nodules and alveolar opacities that mimic PTLD on imaging studies.", "contents": "Posttransplantation Cancer -- Differential Diagnosis. PTLD: Infectious complications streptococcal pharyngitis and Infectious mononucleosis\u00a0in an immunosuppressed\u00a0individual presenting with fever, pharyngitis, and cervical lymphadenopathy closely mimic PTLD. Solid-organ recipients with opportunistic pulmonary infections such as aspergillosis and acute graft-versus-host disease may develop multiple lung parenchymal nodules and alveolar opacities that mimic PTLD on imaging studies."}
{"id": "article-27562_26", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "Melanoma: Mucosal fungal lesions\u00a0closely mimic mucosal melanoma, so the progression of lesion and cytology may be necessary to treat.", "contents": "Posttransplantation Cancer -- Differential Diagnosis. Melanoma: Mucosal fungal lesions\u00a0closely mimic mucosal melanoma, so the progression of lesion and cytology may be necessary to treat."}
{"id": "article-27562_27", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "Skin cancers:\u00a0keratoacanthoma and solar (actinic) keratosis closely mimic squamous cell carcinoma; an excisional biopsy can differentiate between the two.", "contents": "Posttransplantation Cancer -- Differential Diagnosis. Skin cancers:\u00a0keratoacanthoma and solar (actinic) keratosis closely mimic squamous cell carcinoma; an excisional biopsy can differentiate between the two."}
{"id": "article-27562_28", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "CNS Lymphoma: CMV or Toxoplasma are common viral and parasitic infections in an immunosuppressed\u00a0individual, they present as ring-enhancing lesions in the brain and may be mistaken for primary or secondary CNS lymphoma.", "contents": "Posttransplantation Cancer -- Differential Diagnosis. CNS Lymphoma: CMV or Toxoplasma are common viral and parasitic infections in an immunosuppressed\u00a0individual, they present as ring-enhancing lesions in the brain and may be mistaken for primary or secondary CNS lymphoma."}
{"id": "article-27562_29", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "Benign conditions of the transplanted kidney, liver, and lungs can manifest as space-occupying lesions and mimic posttransplant malignancies. Renal pathologic conditions such as transplant-related fibrosis, acute pyelonephritis, and subcapsular hematoma may mimic malignancies un ultrasound and CT.", "contents": "Posttransplantation Cancer -- Differential Diagnosis. Benign conditions of the transplanted kidney, liver, and lungs can manifest as space-occupying lesions and mimic posttransplant malignancies. Renal pathologic conditions such as transplant-related fibrosis, acute pyelonephritis, and subcapsular hematoma may mimic malignancies un ultrasound and CT."}
{"id": "article-27562_30", "title": "Posttransplantation Cancer -- Differential Diagnosis", "content": "Ischemia and reperfusion injury to the liver transplant may cause biliary necrosis and hepatic infarcts or micro-abscesses that may mimic recurrent HCCs at imaging studies. [18]", "contents": "Posttransplantation Cancer -- Differential Diagnosis. Ischemia and reperfusion injury to the liver transplant may cause biliary necrosis and hepatic infarcts or micro-abscesses that may mimic recurrent HCCs at imaging studies. [18]"}
{"id": "article-27562_31", "title": "Posttransplantation Cancer -- Prognosis", "content": "Malignant neoplasms after transplantation have different\u00a0clinical features that are\u00a0responsible for higher mortality. The Israel Penn International Transplant Tumor Registry showed that the stage-specific survival for cancer of colon, lung, breast, prostate, and bladder, was\u00a0lower in patients after solid organ transplant compared with those without it.\u00a0The 1-year adjusted survival of recipients with colorectal, prostate and non-small-cell lung cancer were 10%, 40%, and 20%, respectively, compared with 40%, 80%, and 30% in the general population. [19] Farrugia\u00a0et al. reported that\u00a0the overall risk of cancer death after transplantation was tenfold as compared to\u00a0age- and sex-matched population. [20]", "contents": "Posttransplantation Cancer -- Prognosis. Malignant neoplasms after transplantation have different\u00a0clinical features that are\u00a0responsible for higher mortality. The Israel Penn International Transplant Tumor Registry showed that the stage-specific survival for cancer of colon, lung, breast, prostate, and bladder, was\u00a0lower in patients after solid organ transplant compared with those without it.\u00a0The 1-year adjusted survival of recipients with colorectal, prostate and non-small-cell lung cancer were 10%, 40%, and 20%, respectively, compared with 40%, 80%, and 30% in the general population. [19] Farrugia\u00a0et al. reported that\u00a0the overall risk of cancer death after transplantation was tenfold as compared to\u00a0age- and sex-matched population. [20]"}
{"id": "article-27562_32", "title": "Posttransplantation Cancer -- Complications", "content": "Complications because of post-transplant cancer\u00a0are decreased quality of life, death, and increased healthcare spending.", "contents": "Posttransplantation Cancer -- Complications. Complications because of post-transplant cancer\u00a0are decreased quality of life, death, and increased healthcare spending."}
{"id": "article-27562_33", "title": "Posttransplantation Cancer -- Deterrence and Patient Education", "content": "The solid organ recipients should be counseled\u00a0and taught to remain vigilant of this potential problem. The National Kidney Foundation conducted a survey about whether transplant recipients remembered receiving information about the risk of cancer and other complications. The results were not promising as only one-third of these patients recalled receiving information from a health care professional about cancer risks before the procedure. One fourth (23%) of all the patients learned about the risk of post-transplant cancer only after their surgery. Filling this void a priority and detailed conversation before transplant and on follow-up visits need to take place. The patients should receive counseling regarding the risk factors that can be controlled or manipulated (e.g., immunosuppressive drugs, untreated viral infections), there is a window of opportunity\u00a0to prevent post-transplant cancers. Thus, lies the importance\u00a0of constant patient education. [21] Providing education and screening tools for all patients in the postoperative period ensures an extension of the provider's knowledge into the hands of the patients.", "contents": "Posttransplantation Cancer -- Deterrence and Patient Education. The solid organ recipients should be counseled\u00a0and taught to remain vigilant of this potential problem. The National Kidney Foundation conducted a survey about whether transplant recipients remembered receiving information about the risk of cancer and other complications. The results were not promising as only one-third of these patients recalled receiving information from a health care professional about cancer risks before the procedure. One fourth (23%) of all the patients learned about the risk of post-transplant cancer only after their surgery. Filling this void a priority and detailed conversation before transplant and on follow-up visits need to take place. The patients should receive counseling regarding the risk factors that can be controlled or manipulated (e.g., immunosuppressive drugs, untreated viral infections), there is a window of opportunity\u00a0to prevent post-transplant cancers. Thus, lies the importance\u00a0of constant patient education. [21] Providing education and screening tools for all patients in the postoperative period ensures an extension of the provider's knowledge into the hands of the patients."}
{"id": "article-27562_34", "title": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes", "content": "Successful organ transplantation and good quality of life for patients requires all members of the healthcare team to work together to provide bedside care, education, physical and psychosocial support, and continued follow-up examinations. Educating residents, organ transplant coordinators, specialty trained nurses, pharmacists, and mid-level practitioners on the latest research are vital in promoting the best perioperative and postoperative care. [22]", "contents": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes. Successful organ transplantation and good quality of life for patients requires all members of the healthcare team to work together to provide bedside care, education, physical and psychosocial support, and continued follow-up examinations. Educating residents, organ transplant coordinators, specialty trained nurses, pharmacists, and mid-level practitioners on the latest research are vital in promoting the best perioperative and postoperative care. [22]"}
{"id": "article-27562_35", "title": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes", "content": "Cancer screening and\u00a0surveillance should be standard practice for healthcare policies in clinics and hospitals. All members of the team should\u00a0be\u00a0made\u00a0aware of dermatological inspections, sun protection programs, and\u00a0self-screening tools\u00a0for all patients as a protocol in the posttransplant period. All the protocols should be standardized. [23]", "contents": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes. Cancer screening and\u00a0surveillance should be standard practice for healthcare policies in clinics and hospitals. All members of the team should\u00a0be\u00a0made\u00a0aware of dermatological inspections, sun protection programs, and\u00a0self-screening tools\u00a0for all patients as a protocol in the posttransplant period. All the protocols should be standardized. [23]"}
{"id": "article-27562_36", "title": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes", "content": "Transplant nurses arrange follow up for these patients, provide education to the patients and their families, monitor patient status, and provide feedback to the team. Pharmacists counsel patients about side effects, screen for drug-drug interactions, and assess compliance. These measures improve outcomes. [Level 5]", "contents": "Posttransplantation Cancer -- Enhancing Healthcare Team Outcomes. Transplant nurses arrange follow up for these patients, provide education to the patients and their families, monitor patient status, and provide feedback to the team. Pharmacists counsel patients about side effects, screen for drug-drug interactions, and assess compliance. These measures improve outcomes. [Level 5]"}
{"id": "article-27562_37", "title": "Posttransplantation Cancer -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Posttransplantation Cancer -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}